Klein Lawrence Otto
Company insiders · Chief Executive Officer · Director · Oruka Therapeutics, Inc.
- Reported transaction lines
- 7
- Buy lines
- 0
- Sell lines
- 5
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-117
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Employee Warrant (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 1503513 · The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. | 2026-11-02 | 2026-11-02 | 25,000 shares/units | SEC 4 |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 923128 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.40 to $98.41, inclusive. | 2026-11-02 | 2026-11-02 | ≈ $29,520.99 300 shares/units | SEC 4 |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 923428 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.30 to $98.12, inclusive. | 2026-11-02 | 2026-11-02 | ≈ $73,675.53 756 shares/units | SEC 4 |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 924184 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.25 to $97.24, inclusive. | 2026-11-02 | 2026-11-02 | ≈ $236,146.53 2,442 shares/units | SEC 4 |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 926626 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.25 to $96.23, inclusive. | 2026-11-02 | 2026-11-02 | ≈ $1,437,987.41 15,036 shares/units | SEC 4 |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 941662 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.25 to $95.24, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. | 2026-11-02 | 2026-11-02 | ≈ $612,794.46 6,466 shares/units | SEC 4 |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 948128 | 2026-11-02 | 2026-11-02 | 25,000 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.